Malcolm Whitman from 2101 Belmont Rd, Ann Arbor, MI 48104, Phone: (734)6628593

Malcolm Whitman

view source

Malcolm "Mal" Douglass Whitman (born March 15, 1877, New York December 28, 1932, New York) was an American male tennis player. Whitman is best known for this hat trick at the U.S ...

Tennis: Origins and Mysteries

view source

Author
Malcolm D. Whitman

ISBN #
0486433579

Tennis: Origins and Mysteries

view source

Author
Malcolm D. Whitman

ISBN #
0810335425

Dr. Malcolm Whitman, Milford MA - DMD (Doctor of Dental Medicine)

view source

Specialties:

Dentistry

Address:

8 Asylum St, Milford, MA 01757
(508)4737632 (Phone)

Languages:

English

Us Patents

Methods And Reagents For Modulating Tgf-Beta Superfamily Signalling
view source
US Patent:

20020160355, Oct 31, 2002
Filed:

Jan 11, 2002
Appl. No.:

10/044442
Inventors:

Malcolm Whitman - Boston MA, US
Xin Chen - Mountain View CA, US
International Classification:

C12Q001/00
C12Q001/68
US Classification:

435/004000, 435/006000
Abstract:

FAST-and Smad2 or Smad3 form a complex that is specifically induced by signals generated by a TGF- superfamily member. We have shown that a domain of FAST-directly interacts with Smad2 or Smad3, and that this interaction is mediated by specific domains of the two interacting molecules, namely, the MH2 domain of Smad2 or Smad3 and the Smad Interaction Domain (SID) of FAST-. This result allows the development of methods and reagents for the isolation of compounds that are involved in, and/or modulate, TGF- superfamily signalling.

Methods For Modulating Formation And Progression Of Cellulite
view source
US Patent:

20080025917, Jan 31, 2008
Filed:

Apr 10, 2007
Appl. No.:

11/786151
Inventors:

Malcolm Whitman - Jamaica Plain MA, US
Tracy Keller - Jamaica Plain MA, US
International Classification:

A61K 31/517
A61K 49/00
A61P 17/00
C12Q 1/02
G01N 33/53
US Classification:

424009200, 435029000, 435007100, 514266220, 514789000
Abstract:

This invention provides methods and compositions for modulating the formation and/or progression of cellulite and other skin disorders in a subject.

Methods For Modulating Th17 Cell Development In The Treatment And Prevention Of Cellulite
view source
US Patent:

20090123389, May 14, 2009
Filed:

Aug 15, 2008
Appl. No.:

12/228799
Inventors:

Malcolm Whitman - Jamaica Plain MA, US
Tracy Keller - Jamaica Plain MA, US
International Classification:

A61K 31/517
A61K 9/12
US Classification:

424 45, 51426622
Abstract:

This invention relates generally to methods and compositions for modulating the development of Th17 cells for use, for example, in the treatment of cellulite.

Methods For Modulating Development And Expansion Of Il-17 Expressing Cells
view source
US Patent:

20110212100, Sep 1, 2011
Filed:

Aug 15, 2008
Appl. No.:

12/673119
Inventors:

Tracy Keller - Jamaica Plain MA, US
Malcolm Whitman - Jamaica Plain MA, US
Mark S. Sundrud - Brookline MA, US
Anjana Rao - Cambridge MA, US
International Classification:

A61K 31/517
A61K 39/395
A61P 37/06
A61P 29/00
A61P 31/00
US Classification:

4241581, 51426622
Abstract:

This invention provides methods and compositions for modulating the development and/or expansion of Th17 cells for use, for example, in the treatment of autoimmune diseases, persistent inflammatory diseases, infectious diseases and other Th17 related and/or IL-17 related diseases.

Halofuginone Analogs For Inhibition Of Trna Synthetases And Uses Thereof
view source
US Patent:

20110263532, Oct 27, 2011
Filed:

Aug 11, 2009
Appl. No.:

13/058486
Inventors:

Tracy Keller - Jamaica Plain MA, US
Ralph Mazitschek - Arlington MA, US
Malcolm Whitman - Jamaica Plain MA, US
Jinbo Lee - Andover MA, US
Assignee:

President and Fellows of Harvard College - Cambridge MA
International Classification:

A61K 31/675
A61K 31/517
C07F 7/10
A61K 31/695
C07D 401/14
C07D 413/14
A61K 31/5377
C07D 487/04
A61K 31/519
C07D 495/04
C07F 9/6558
C07D 405/14
A61P 37/06
A61P 35/00
A61P 29/02
A61P 33/02
A61P 43/00
C07D 401/12
US Classification:

514 80, 544287, 51426622, 544229, 514 63, 544284, 544116, 5142345, 544256, 5142662, 51426621, 5142621, 544244, 544278, 5142601
Abstract:

The present invention provides novel analogs and derivatives of halofuginone. The invention also provides pharmaceutical and cosmetic compositions thereof and methods for using halofuginone analogs in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, ischemic damage, transplant and implant rejection, neurodegenerative diseases, and cosmetic applications.

Inhibition Of Trna Synthetases And Therapeutic Applications Thereof
view source
US Patent:

20120058133, Mar 8, 2012
Filed:

Feb 17, 2010
Appl. No.:

13/201933
Inventors:

Malcolm Whitman - Jamaica Plain MA, US
Tracy Keller - Jamaica Plain MA, US
Assignee:

President and Fellows of Harvard College - Cambridge MA
International Classification:

A61K 35/00
A61K 31/7076
A61P 29/00
A61P 31/00
A61P 11/06
C12N 5/0783
C12Q 1/25
G01N 21/64
C12Q 1/68
G01N 33/566
C40B 30/04
A61K 31/519
A61K 31/473
A61K 31/47
A61K 31/4704
A61K 31/5375
A61K 31/137
A61P 37/06
US Classification:

4241841, 435377, 435 29, 435 71, 435 612, 435 724, 506 9
Abstract:

The present invention provides novel methods for modulating Th 17-mediated immune responses using aminoacyl tRNA synthetase inhibitors. Inhibition of aminoacyl tRNA synthetase inhibitors activates an amino acid starvation response (AAR) and can produce beneficial therapeutic effects. In some embodiments, aminoacyl tRNA synthetase inhibitors are used to treat disorders such as autoimmune diseases, graft rejection, infections, fibrosis, and inflammatory diseases.

Methods And Reagents For Modulating Tgf- Superfamily Signalling
view source
US Patent:

6365711, Apr 2, 2002
Filed:

May 28, 1998
Appl. No.:

09/087134
Inventors:

Malcolm Whitman - Boston MA
Xin Chen - Mountain View CA
Assignee:

President and Fellows of Harvard College - Cambridge MA
International Classification:

C07K 1447
US Classification:

530300, 530350
Abstract:

FAST-1 and Smad2 or Smad3 form a complex that is specifically induced by signals generated by a TGF- superfamily member. We have shown that a domain of FAST-1 directly interacts with Smad2 or Smad3, and that this interaction is mediated by specific domains of the two interacting molecules, namely, the MH2 domain of Smad2 or Smad3 and the Smad Interaction Domain (SID) of FAST-1. This result allows the development of methods and reagents for the isolation of compounds that are involved in, and/or modulate, TGF- superfamily signalling.

Halofuginone Analogs For Inhibition Of Trna Synthetases And Uses Thereof
view source
US Patent:

20160317498, Nov 3, 2016
Filed:

Mar 8, 2016
Appl. No.:

15/064198
Inventors:

- Cambridge MA, US
- Boston MA, US
Malcolm Whitman - Jamaica Plain MA, US
Jinbo Lee - Andover MA, US
Mark S. Sundrud - Jupiter FL, US
Anjana Rao - La Jolla CA, US
Assignee:

President and Fellows of Harvard College - Cambridge MA
Children's Medical Center Corporation - Boston MA
International Classification:

A61K 31/4184
A61K 31/685
A61K 31/695
Abstract:

The present invention provides novel analogs and derivatives of halofuginone. The invention also provides pharmaceutical and cosmetic compositions thereof and methods for using halofuginone analogs in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, ischemic damage, transplant and implant rejection, neurodegenerative diseases, and cosmetic applications.